UNC Researchers to Use Artificial Intelligence to Develop Cancer Vaccine
With a $40 million grant provided by the OpenAI foundation, UNC-Chapel Hill is initiating work in this field.
UNC-Chapel Hill researchers have received $40 million over four years from the OpenAI foundation to use artificial intelligence technology to develop personalized cancer vaccines.
Generative Immunotherapy Project
The project, to be conducted at UNC-Chapel Hill and named Generative Immunotherapy, aims to produce patient-specific cancer vaccines through artificial intelligence.
First Clinical Trials
Dr. Benjamin Vincent, co-director of the project, stated that the initial clinical trials will be conducted on triple-negative breast cancer patients who are at a high risk of recurrence after surgical removal of the tumor.
Artificial Intelligence and Data Collection
Over the next four years, data will be collected from 75 patients, and this data will be transferred to computer systems to develop artificial intelligence models.
Future Goals and Cost
Researchers aim to ensure that these vaccines become more affordable and accessible in the future following legal and technical processes.